Introduction: Sarcoid polyneuropathy is a rare and clinically heterogeneous disorder that
INTRODUCTION
Sarcoidosis is a rare multisystem granulomatous disorder that typically affects lungs, lymph nodes, skin, and eyes. It affects women more commonly than men, with a prevalence of approximately 10/100,000 in Caucasian populations and approximately 35/100,000 in African Americans. 1 Clinical involvement of the central or peripheral nervous system occurs in 5-15% of cases, although there is likely a significant proportion of subclinical neurosarcoidosis. 2 Isolated neurosarcoidosis without systemic signs may occur in 20% of patients with neurological involvement. The most common neurological manifestations of sarcoidosis include optic neuritis, cranial neuropathies, and myelopathies. Peripheral polyneuropathy is rare, although there are reports of acute Guillain-Barré Syndrome (GBS)-like presentations, focal or multifocal axonal polyneuropathies, and demyelinating polyneuropathies. 2, 3 Peripheral nervous system involvement is usually accompanied by systemic signs of sarcoidosis, 4 but sometimes it is the presenting symptom. 5 We report the clinical course and histological findings of a patient with sarcoid polyneuropathy masquerading as chronic inflammatory demyelinating polyneuropathy (CIDP).
CASE REPORT
A 36 year-old African-American man with a diagnosis of CIDP for the past decade presented with several weeks of muscle pain and cramps, weakness in his lower extremities leading to falls, and dysesthesias. Peripheral neuropathy is a rare manifestation of sarcoidosis, affecting only 2% of patients. 8 Patterns of peripheral nerve involvement due to sarcoidosis are varied and include distal symmetric polyneuropathy, focal or multifocal neuropathy, and mononeuritis multiplex. 9,2 Sarcoidosis has also been reported to present with an acute GBS-like inflammatory polyneuropathy, and as in this case, associated with electrodiagnostic evidence of demyelinating neuropathy and conduction block. [10] [11] [12] 3 In a retrospective cohort of 57 patients with biopsy-proven sarcoid neuropathy, positive neuropathic sensory symptoms, including pain, were more prominent than weakness and sensory loss. 4 In this cohort, asymmetric, non-length dependent axonal polyneuropathy predominated, although an acquired demyelinating process with conduction block was observed in 3 patients. Patients typically had associated systemic symptoms and a chronic progressive disease course, but good functional outcomes with steroid treatment.
A neuropathological analysis of 11 cases of sarcoidosis with nerve granulomas observed on sural nerve biopsy also revealed a wide range of peripheral nerve abnormalities. 5 Five patients had predominantly sensory findings on clinical examination, and 8 patients had axonal sensory-motor multifocal neuropathy on electrophysiological studies; nerve biopsy studies showed endoneurial infiltrates and epineurial granulomata in all specimens. It is unclear how granulomatous disease causes neuropathic symptoms and demyelination, although it may be significant that granulomata may remain asymptomatic if they are confined to the epineurium. 13 In addition, necrotizing vasculitis was observed in association with granulomata in 6 patients. Thus, symptoms of neuropathy may be secondary to vasculitis-related nerve ischemia and granuloma- Evidence-based guidance for treatment of neurosarcoidosis is limited by its rarity.
Glucocorticoids are considered the first-line treatment, although in refractory cases a second immune modulator is often added. Methotrexate is usually second line treatment in pulmonary sarcoidosis, and a few studies suggest it may be useful in neurosarcoidosis.
There are also reports of benefit from IVIg. 9 Treatment with infliximab, which inhibits tumor necrosis factor-alpha, has demonstrated benefit in a randomized controlled trial when it was given to 138 patients with extrapulmonary sarcoidosis (8% of whom had peripheral nerve involvement). 15 Fewer than 10 % of patients do not respond to any immune modulatory therapy.
In summary, we describe a patient sarcoid polyneuropathy mimicking sensorypredominant CIDP for over a decade until he developed systemic symptoms that led to the correct diagnosis. Sarcoid polyneuropathy is not only rare, but it also presents with a variety of clinical syndromes which often delay the diagnosis of this challenging disorder. Thus, in patients with atypical symptomatology or poor response to therapy, particularly in the setting of systemic symptoms, we recommend a clinical and laboratory search for sarcoidosis. In cases of suspected peripheral nerve sarcoidosis, biopsy of both nerve and muscle tissue may increase the diagnostic yield and help rule out other rare inflammatory, infectious, or neoplastic causes of neuropathies. 
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